Qiagen N.V. (NASDAQ:QGEN) was upgraded by TheStreet from a “hold” rating to a “buy” rating in a research note issued on Friday, StockRatingsNetwork reports.
The analysts wrote, “Qiagen (QGEN) has been upgraded by TheStreet Ratings from hold to buy. The company’s strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.”
Qiagen N.V. (NASDAQ:QGEN) traded down 0.38% on Friday, hitting $23.51. The stock had a trading volume of 49,018 shares. Qiagen N.V. has a 52 week low of $17.57 and a 52 week high of $24.74. The stock has a 50-day moving average of $22.42 and a 200-day moving average of $20.81. The company has a market cap of $5.512 billion and a price-to-earnings ratio of 118.00.
Qiagen N.V. (NASDAQ:QGEN) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.28 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.25 by $0.03. The company had revenue of $323.80 million for the quarter, compared to the consensus estimate of $320.37 million. During the same quarter last year, the company posted $0.26 earnings per share. Qiagen N.V.’s revenue was up 6.4% compared to the same quarter last year. Analysts expect that Qiagen N.V. will post $1.02 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. upgraded shares of Qiagen N.V. from a “sell” rating to a “neutral” rating in a research note to investors on Tuesday, November 19th. They now have a $24.00 price target on the stock, up previously from $18.00. Separately, analysts at Cowen and Company upgraded shares of Qiagen N.V. from an “underperform” rating to a “market perform” rating in a research note to investors on Thursday, October 31st. They now have a $21.00 price target on the stock, up previously from $15.50. Finally, analysts at BNP Paribas downgraded shares of Qiagen N.V. from a “neutral” rating to an “underperform” rating in a research note to investors on Friday, October 4th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $21.84.
QIAGEN N.V., (NASDAQ:QGEN) is a holding company, which provides sample and assay technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.